Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
|Articles|August 23, 2022
Daily Medication Pearl: Seizalam
Author(s)Saro Arakelians, PharmD
Seizalam is a benzodiazepine indicated for the treatment of status epilepticus in adults.
Advertisement
Medication Pearl of the Day: Midazolam injection (Seizalam)
Indication: Seizalam is a benzodiazepine indicated for the treatment of status epilepticus in adults.
Insight:
- Dosing: Injection: 50 mg/10 mL (5 mg/mL) in a multiple-dose vial.
- Dosage forms: The recommended dose is 10 mg, administered by intramuscular injection.
- Adverse events: The most common adverse reactions (incidence >3%) in clinical trials in patients with status epilepticus were upper airway obstruction, agitation, and pyrexia.
- Mechanism of action: The exact mechanism of action for midazolam in the treatment of status epilepticus is not fully understood but is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABAA receptor.
Source:
Advertisement
Related to this article
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder that primarily affects the nervous system, causing progressive loss of muscle control and coordination.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
5